|
|
| (5 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{Undifferentiated connective tissue disease}} | | {{Undifferentiated connective tissue disease}} |
| {{CMG}} {{AE}} | | {{CMG}} {{AE}}{{ADS}} |
|
| |
|
| ==Overview== | | ==Overview== |
| There is no treatment for [disease name]; the mainstay of therapy is supportive care.
| | The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as [[methotrexate]] in those exhibiting [[arthritis]] and [[dermatitis]]. Supportive therapy includes; avoiding cold exposure in those experiencing [[Raynaud's phenomenon]], avoiding sun in [[photosensitivity]], [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]] for pain control, [[sunscreen]] used for [[photosensitivity]], and [[emollients]] for dry skin and rash. |
|
| |
|
| OR
| | ==Medical Therapy== |
| | |
| Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
| |
| | |
| OR
| |
| | |
| The majority of cases of [disease name] are self-limited and require only supportive care.
| |
| | |
| OR
| |
| | |
| [Disease name] is a medical emergency and requires prompt treatment.
| |
| | |
| OR
| |
| | |
| The mainstay of treatment for [disease name] is [therapy].
| |
| | |
| OR
| |
|
| |
| The optimal therapy for [malignancy name] depends on the stage at diagnosis.
| |
| | |
| OR
| |
| | |
| [Therapy] is recommended among all patients who develop [disease name].
| |
| | |
| OR
| |
| | |
| Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
| |
| | |
| OR
| |
| | |
| Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
| |
| | |
| OR
| |
|
| |
|
| Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
| | === Routine measures === |
| | | * Avoiding cold exposure in those experiencing [[Raynaud's phenomenon]] |
| OR
| | * Avoiding sun in [[photosensitivity]] |
| | |
| Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
| |
| | |
| ==Medical Therapy== | |
| *Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3]. | |
| *Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3]. | |
| *Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
| |
| *Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
| |
| ===Disease Name===
| |
|
| |
|
| * '''1 Stage 1 - Name of stage'''
| | === Supportive therapy === |
| ** 1.1 '''Specific Organ system involved 1''' | | * [[Non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drugs]] for pain control |
| *** 1.1.1 '''Adult'''
| | * [[Sunscreen]] used for [[photosensitivity]] |
| **** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''
| | * [[Emollients]] for dry skin, rash |
| **** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
| |
| **** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
| |
| **** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days | |
| **** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| **** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days | |
| *** 1.1.2 '''Pediatric'''
| |
| **** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
| |
| ****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
| |
| ***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
| |
| ** 1.2 '''Specific Organ system involved 2'''
| |
| *** 1.2.1 '''Adult'''
| |
| **** Preferred regimen (1): [[drug name]] 500 mg PO q8h
| |
| *** 1.2.2 '''Pediatric'''
| |
| **** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
| |
|
| |
|
| * 2 '''Stage 2 - Name of stage'''
| | === Arthritis and dermatitis === |
| ** 2.1 '''Specific Organ system involved 1 '''
| | *Oral regimen |
| **: '''Note (1):'''
| | **Preferred regimen (1): [[Methotrexate]] 7.5 mg PO q24h for 6 months '''(not used for CNS symptoms or serositis)'''<ref name="pmid8782131">{{cite journal |vauthors=Wise CM, Vuyyuru S, Roberts WN |title=Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients |journal=J. Rheumatol. |volume=23 |issue=6 |pages=1005–10 |date=June 1996 |pmid=8782131 |doi= |url=}}</ref> |
| **: '''Note (2)''':
| | *** Dose can be gradually increased to 13.6 mg after 6 months |
| **: '''Note (3):'''
| |
| *** 2.1.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.1.2 '''Pediatric'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
| |
| ** 2.2 '<nowiki/>'''''Other Organ system involved 2''''''
| |
| **: '''Note (1):''' | |
| **: '''Note (2)''': | |
| **: '''Note (3):'''
| |
| *** 2.2.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.2.2 '''Pediatric'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
| |
|
| |
|
| ==References== | | ==References== |